Nuveen Asset Management, LLC Genmab A/S Transaction History

Nuveen Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$26.83 - $38.57 $18.4 Million - $26.4 Million	-684,858 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$30.95 - $39.68 $275,455 - $353,152	-8,900 Reduced 1.28%	684,858 $24.8 Million
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $594,186 - $780,542	-16,565 Reduced 2.33%	693,758 $27.4 Million
Q3 2021 Nov 12, 2021	BUY	$41.55 - $48.72 $722,180 - $846,802	17,381 Added 2.51%	710,323 $31 Million
Q2 2021 Aug 16, 2021	BUY	$32.88 - $44.57 $6.33 Million - $8.58 Million	192,502 Added 38.47%	692,942 $28.3 Million
Q1 2021 May 17, 2021	SELL	$30.92 - $44.4 $249,215 - $357,864	-8,060 Reduced 1.59%	500,440 $16.4 Million
Q4 2020 Feb 16, 2021	SELL	$33.66 - $40.76 $2.7 Million - $3.27 Million	-80,256 Reduced 13.63%	508,500 $20.7 Million
Q3 2020 Nov 16, 2020	BUY	$33.07 - $38.68 $19.5 Million - $22.8 Million	588,756 New	588,756 $21.6 Million

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.